Title: SARS-coV2 variants Evaluation in pRegnancy and paeDIatrics cohorts.
GA Number: 101045989
Background: Since its emergence in 2019, SARS-CoV-2 has been a ‘moving target’, with different variants of concern emerging across the world, which may increase the transmissibility, severity and immune evasion of the virus. Children and pregnant women can be more vulnerable to infection outbreaks. Monitoring these groups across regions is crucial given rapid changes in epidemiology due to varying country-level interventions, vaccine rollout, booster programmes and viral evolution, which have global effects.
As with SARS-CoV-2 and its variants, the future of the mpox outbreak in non-endemic countries remains uncertain. Therefore, it is important to continue to monitor the epidemiology in currently affected groups – particularly people living with or at high risk of HIV – as well as children and pregnant women, who could become more severely affected if there is more widespread infection in the community.
VERDI aims to address these issues by answering research questions on the impact of SARS-CoV-2 variants of concern in pregnant women, infants, children and adolescents primarily through observational cohort studies. VERDI will also focus on populations at increased risk for mpox, such as people living with HIV and people attending sexual health clinics.
Finally, VERDI will develop research preparedness in case there are changes in the ongoing outbreaks and possible (re-)emergence of future infections. The network will build on the well-established cohort partners involved across the world.
UNIPD, Università degli Studi di Padova - ITALY
UCL, University College London - UK
UMCU, Universitair Medisch Centrum Utrecht - NETHERLANDS
UO, Universitetet I Oslo - NORWAY
ISI, Istituto per l'Intersambio Scientifico - ITALY
CONENO, Coneno GMBH - DENMARK
INSERM, Institut National de la Sante Et de la Recherche Medicale - FRANCE
MU, Mahidol University - THAILAND
CMU, Chiang Mai University - THAILAND
UNIVR, Università di Verona - ITALY
PENTA, Fondazione PENTA Onlus - ITALY
GHESKIO, Les Centres Gheskio - HAITI
UCT, University of Cape Town - SOUTH AFRICA
SU, Stellenbosch University - SOUTH AFRICA
FBK, Fondazione Bruno Kessler - ITALY
CLALIT, Mor Research Applications LTD - ISREAL
UHASSELT, Universiteit Hasselt - BELGIUM
IZSVE, Istituto Zooprofilattico Sperimentale delle Venezie - ITALY
UANTWERPEN, Universiteit Antwerpen - BELGIUM
UNIBAS, Universitat Basel - SWITZERLAND
UKBB, Universitats-kinderspital Beider Basel - SWITZERLAND (associated partner)
IMPERIAL, Imperial College of Science Technology and Medicine - UK
UF, University of Florida - US
EUC, European University - Cyprus LTD - CYPRUS
NEAT ID, neat ID Foundation - BELGIUM
IHVN, Institute of Human Virology Nigeria LTDGTE - NIGERIA
SERMAS, Servicio Madrileno de Salud - SPAIN
FIB-H120, Fundacion para la Investigacion Biomedica del Hospital Universitario 12 de Octubre - SPAIN (affiliated entity)
FIBHGM, Fundacion para la Investigacion Biomedica del Hospital Gregorio Maranon - SPAIN (affiliated entity)
FIBHULP, Fundacion para la Investigacion Biomedica del Hospital Universiatrio La Paz - SPAIN (affiliated entity)
ULIEGE, Universite de Liege - BELGIUM
PEDIANET, Società Servizi Telematici SRL - ITALY
UTartu, Tartu Ulikool - ESTONIA
Clinical Microbiology and Infection
Perpetual observational studies: new strategies to support efficient implementation of observational studies and randomized trials in infectious diseases